The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I); ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; CarThera; Celldex; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Merck; Novogen; Omniox; Oxigene; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Boston Biomedical; Bristol-Myers Squibb; Celgene; Celldex; cortice; CytRx Corporation; Human Longevity, Inc; Insys Therapeutics; Merck; Nektar; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pfizer; ProNAi; Roche/Genentech; Sunovion; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust
 
Marshall W. Pitz
No Relationships to Disclose
 
Yoshitaka Narita
Honoraria - Abbvie; Chugai Pharma; Daiichi Sankyo; Eisai; Merck Sharp & Dohme; Otsuka
Consulting or Advisory Role - Abbvie; Sumitomo Dainippon
Research Funding - Abbvie; Chugai Pharma; Daiichi Sankyo; Eisai; EPS Associates Co., Ltd.; GlaxoSmithKline; Meiji Seika Kaisha; Merck Sharp & Dohme; Ono Pharmaceutical; Otsuka; SBI Pharmaceuticals; Stella pharma; Toshiba
 
Takeshi Nonomura
Employment - Boston Biomedical